


About Us
Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. Xynomic Pharma focus on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Partnerships with MNCs including Pharmacyclics/AbbVie, Boehringer Ingelheim and Janssen.
Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin’s lymphoma (as a single agent). Abexinostat has granted 2 Fast-Track designations from FDA. Xynomic’s XP-105 (BI 860585) is a Phase 2 ready, ATP-competitive mTORC1/2 inhibitor against solid tumors. Xynomic’s XP-102 (BI 882370) is a Phase 1 ready pan-RAF inhibitor.
Xynomic Pharma founded by experienced multinational veterans and successful entrepreneurs. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies.
Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and rest of the world. Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner.
Xynomic Pharma is headquartered in the Shanghai with major operations in US and Shanghai, China.
Latest News
-
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
09/26/2019September 23, 2019 06:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details -
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor
09/26/2019September 13, 2019 15:58 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details -
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
09/26/2019August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details -
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
09/01/2019August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details -
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors
08/20/2019August 16, 2019 16:30 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details -
Xynomic Pharma Receives Important Accreditation from Independent Ethics Committees of Leading Chinese Cancer Hospitals
08/14/2019August 07, 2019 16:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 07, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details -
Xynomic Filed Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA
08/14/2019August 01, 2019 07:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 01, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug
Details -
Xynomic Received China Approval to Start 2 Pivotal Lymphoma Clinical Trials
07/31/2019July 30, 2019 07:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, July 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details -
Xynomic Pharma Will Present at 3rd World-China Immunotherapy & Gene Therapy Congress
07/26/2019July 26, 2019 12:29 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, July 26, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug
Details -
Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer
06/14/2019RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the
Details -
Xynomic Dosed First Patient in Phase 1/2 Lymphoma Trial
06/14/2019RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a
Details -
Xynomic Pharma To Present Long-Term Follow Up Data Showing Abexinostat, Combined with Pazopanib, has Durable Responses in Patients with Pre-Treated Kidney Cancer
05/22/2019RALEIGH, N.C. and SHANGHAI, May 21, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company (XYN), announced today that long-term follow up data of exceptional responders to
Details -
Xynomic Pharma 2019 ASCO Annual Meeting Abstracts
05/16/2019Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN), a clinical stage US-China oncology drug development company, and its collaborators will present at the American Society of Clinical Oncology (“ASCO”) 2019 Annual Meeting to be held in Chicago from May 31, 2019 – June
Details -
Mr. Y. Mark Xu, Chairman of Xynomic Pharma Participated in the “BioPharma Investment and Partnering in China” Panel Discussion Hosted by Bayer
04/02/2019On Thursday, March 28th, Bayer, ChinaBio and Shanghai Healthcare Drinks held a discussion panel entitled “BioPharma Investment and Partnering in China”. The event was hosted by Bayer at its Shanghai Pudong Office, where it brought
Details -
Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer
04/02/2019RALEIGH, N.C. and SHANGHAI, March 20, 2019 /PRNewswire/ — Xynomic Pharmaceuticals, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corporation (Nasdaq: BCAC), jointly announced that Xynomic and its collaborators will present at the American Society
Details -
Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials
04/02/2019RALEIGH, N.C. and SHANGHAI, March 16, 2019 /PRNewswire/ — Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced that China, Spain and Poland authorities have approved Xynomic’s application to conduct potentially pivotal Phase 3 trial
Details -
Xynomic Pharma Doses First South Korean Patient in Phase 3 Renal Cell Carcinoma Trial and Hires Senior Executive Dr. Sophia Paspal to Head Regulatory Affairs and Quality Assurance
02/25/2019RALEIGH, N.C. and SHANGHAI, Feb. 23, 2019 /PRNewswire/ — Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced the dosing of the first South
Details -
Xynomic Pharma Acquires Global Exclusive Rights to Phase 2 Ready mTORC1/2 Inhibitor from Boehringer Ingelheim
12/23/2018Dec 20, 2018, 10:52 ET DOVER, Del. and SHANGHAI, Dec. 20, 2018 /PRNewswire/ — Xynomic Pharmaceuticals, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company, today announced that it has been granted an exclusive, worldwide license to
Details -
Mr. Y. Mark Xu, Chairman of Xynomic Pharma Presented at the BioCentury China Healthcare Summit 2018
11/19/2018China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China
Details -
Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018.
11/07/2018Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018. Mr. Xu will present at 12:55 pm on Tuesday, November
Details -
Bison Capital Acquisition Corp. and Xynomic Pharmaceuticals, Inc. Announce Signing of Definitive Merger Agreement
09/29/2018NEW YORK, NY and SHANGHAI, China, Sept. 12, 2018 (GLOBE NEWSWIRE) –– Bison Capital Acquisition Corp. (“BCAC”, NASDAQ: BCAC) and Xynomic Pharmaceuticals, Inc. (“Xynomic”), a U.S.-China clinical stage innovative oncology drug development company, today jointly
Details -
Mark Xu ( Chairman and CEO of Xynomic ) Invited to Participate in JP Morgan Healthcare Conference
01/04/2018The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
-
Xynomic Pharma Initiates Ph 1/2 Trial Combining Abexinostat with Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)
12/03/2017CHEYENNE, Wyo., Dec. 1, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it will initiate a Ph 1/2 trial, in collaboration with Janssen R&D, LLC (Janssen Pharmaceutical Companies of
Details -
Xynomic Pharma Acquires Global Rights of Boehringer Ingelheim’s BI 882370, a Novel and Potent RAF Inhibitor against Solid Tumors
11/07/2017CHEYENNE, Wyo., Oct. 30, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor,
Details -
Xynonic Invited to Present at the Prestigious Berstein China Oncology Day in Hong Kong on June 21
05/29/2017Mr. Y. Mark Xu, Chairman, CEO and President, has been invited to speak at this high profile conference. Other presenting companies include Roche, Sanofi, Hengrui and Sino Biopharm. The venue is Mandarin Oriental Hotel, Hong
Details -
Xynomic Pharma and UCSF Entered Strategic Partnership in Conducting a Phase 2/3 Trial of Abexinostat against Renal Cell Carcinoma
05/26/2017CHEYENNE, Wyo., May 22, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco (“UCSF”) to conduct
Details -
Abexinostat Significantly Reversed Treatment Resistance in GSK’s Pazopanib- and other VEGF inhibitor-refractory Tumors in a 51-Patients Ph 1b Trail Led by Professor Munster at UCSF
03/17/2017Sponsored by NCI and UCSF 51 patients (72% had received two or more lines of therapy in the locally advanced or metastatic setting), Phase 1b, open-label, dose-escalation/expansion trial of Abexinostat in combination with GSK’s pazopanib
Details -
Xynomic Pharma has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications
03/11/2017March. 8, 2017 — Xynomic Pharmaceuticals, Inc., a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be tested
Details -
Xynomic Pharma Has Acquired Worldwide Rights of Abexinostat
02/25/2017CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ — Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that it has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class
Details